Swiss cancer vaccine biotech Nouscom raises $72M Series C for PhII trials

14 Nov 2023
endpts.com
Vaccine
Basel-based biotech Nouscom has raised €67.5 million ($72.2 million) to bankroll its cancer vaccines as the eight-year-old company looks to capitalize on momentum in the field.
The Series C marks the biotech’s first venture investment in about six years; it last raised a $49 million Series B in late 2017.
“We’ve been careful not to over-commit ourselves on spending as we’ve gone and we’re very data-led, not hope-led, on these things,” operating and business chief Richard Davis told Endpoints News.
Swiss cancer vaccine biotech Nouscom raises $72M Series C for PhII trials
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.